In:
Oncology, S. Karger AG, Vol. 84, No. 4 ( 2013), p. 214-218
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 This study aimed to evaluate the association between 〈 i 〉 BCL 〈 /i 〉 2 single-nucleotide polymorphisms and survival outcome in advanced non-small cell lung cancer (NSCLC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 One hundred and sixty-eight patients with advanced NSCLC who were treated with anti-cancer drugs and could be evaluated for therapeutic response between April 2005 and March 2010 at Kyoto University Hospital were enrolled. DNA was extracted from peripheral blood samples. The 〈 i 〉 BCL2 〈 /i 〉 polymorphisms –938 C & #x2192;A (rs2279115) and +21 A & #x2192;G (rs1801018) were genotyped using the 5′-nuclease assay. The univariate relationship between each independent clinicopathologic variable and 〈 i 〉 BCL2 〈 /i 〉 genotype was examined using Fisher’s exact test. To evaluate risk factors associated with prognosis, a Cox proportional hazards regression model with a step-down procedure was used. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The median survival time of patients with the –938 AA and AC genotypes were significantly shorter than those with the –938 CC genotype (p = 0.027 by log-rank test). Based on multivariate analysis, poor performance status [hazard ratio (HR) 2.424, 95% confidence interval (CI) 1.727–3.262; p 〈 0.0001], non-adenocarcinoma histology (HR 1.512, 95% CI 1.167–1.938; p = 0.0048) and the 〈 i 〉 BCL2 〈 /i 〉 –938 AA + AC genotype (HR 1.219, 95% CI, 1.024–1.456; p = 0.0256) were significant independent prognostic factors for survival. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Polymorphisms in 〈 i 〉 BCL2 〈 /i 〉 may be associated with survival in advanced-stage NSCLC patients who received chemotherapy.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2013
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink